drugset / Trial / NCT03523117

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

NCT03523117

Phase 3 Completed 79 enrolled American Regent, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to demonstrate the efficacy and safety of intravenous ferric carboxymaltose (FCM), compared to oral iron, in pediatric participants who have iron deficiency anemia.

Timeline

Start
2019-01-31
Primary completion
2020-12-22
Completion
2021-01-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferric carboxymaltose Other / unclassified 15 mg/kg Intravenous
Comparator Ferrous Sulfate Diagnostic / imaging agent 6 mg/kg Oral
Comparator Ferrous Sulfate Diagnostic / imaging agent 65 mg Oral